HeartBeam Sets Aug. 13 Call to Review Q2 Results and Strategy for Ambulatory ECG Platform

HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through its ambulatory ECG signal platform, announced it will host a conference call on Aug. 13 at 4:30 p.m. ET to discuss financial results for the second quarter ended June 30, 2026, and provide updates on its strategy to accelerate global adoption of its technology. The call will feature Executive Chairman Richard Ferrari, President and Founder Branislav Vajdic, and Chief Financial Officer Timothy Cruickshank, who will deliver prepared remarks followed by a question-and-answer session.

The announcement underscores HeartBeam's progress in commercializing its cable-free 3D ECG device, which collects electrocardiogram signals from three non-coplanar directions and synthesizes them into a standard 12-lead ECG. The platform is designed for portable use outside medical facilities, enabling physicians to detect cardiac health trends and acute conditions and direct patients to appropriate care. The company received FDA clearance for arrhythmia assessment in December 2024 and for its 12-lead ECG synthesis software in December 2025, as noted in the company's cleared indications for use at https://www.heartbeam.com/indications.

The second-quarter results and strategy update come as HeartBeam holds over 20 issued patents related to its technology enablement. The company's platform aims to redefine cardiac health management by providing actionable heart intelligence wherever the patient is. Investors and stakeholders can access the full press release at https://ibn.fm/sqGLs for additional details.

HeartBeam's focus on ambulatory ECG monitoring addresses a critical need in cardiac care, where early detection of arrhythmias and other conditions can significantly improve patient outcomes. The company's 3D ECG technology represents a shift from traditional, clinic-based ECG systems to portable, patient-centric devices. The upcoming call will likely provide insights into adoption rates, partnerships, and regulatory milestones that could drive growth.

As the company moves forward, its strategy to accelerate global adoption will be key to capturing market share in the competitive cardiac monitoring space. The call on Aug. 13 will offer a comprehensive view of HeartBeam's financial health and strategic direction, providing investors with clarity on its path to commercialization. For more information about HeartBeam and its technology, visit the company's newsroom at https://ibn.fm/BEAT.